Edwards Lifesciences Earnings: Here’s Why Investors are Selling Shares Now

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Edwards Lifesciences Corp. (NYSE:EW) delivered a profit and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 12.81%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Edwards Lifesciences Corp. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased 35.85% to $0.72 in the quarter versus EPS of $0.53 in the year-earlier quarter.

Revenue: Rose 8.17% to $496.7 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Edwards Lifesciences Corp. reported adjusted EPS income of $0.72 per share. By that measure, the company missed the mean analyst estimate of $0.76. It missed the average revenue estimate of $518.6 million.

Quoting Management: “The ongoing adoption in the U.S. drove global transcatheter valve growth of 40 percent,” said Michael A. Mussallem, chairman and CEO. “Our THV clinical results continue to be very positive and we are making good progress on our pipeline of new products that we believe will enable us to strengthen our leadership position. Yet, as global sales this quarter across product lines were below our expectations, we are lowering our 2013 guidance primarily to reflect a slower start to the year and an updated foreign exchange impact.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business